Metronidazole capsules 500mg (Meronidal) is a widely applied synthetic nitroimidazole anti-infective agent with potent anti-anaerobic bacterial and antiprotozoal activities, ranking among the core anti-infective medicines in global primary healthcare systems. It is supplied as oral hard capsules, with the 500mg specification serving as the standard clinical dosage suitable for the management of most infectious diseases in adults and older children. Its prominent advantages include rapid oral absorption, high bioavailability and strong tissue penetration.
After oral administration, the drug is quickly absorbed via the gastrointestinal tract, reaching peak plasma concentrations within 1–2 hours. It distributes extensively throughout human tissues, body fluids and luminal secretions, crosses the blood-brain barrier and placental barrier, and attains bacteriostatic and bactericidal effective concentrations in pus, saliva and breast milk.
our products form
Metronidazole COA
Mechanism of Action and Clinical Applications
Core Mechanism of Action
The anti-infective activity of meronidal strictly depends on anaerobic environments; activation reactions must proceed inside oxygen-free or hypoxic microbial cells to achieve bactericidal and antiprotozoal effects. The entire process consists of multiple precisely regulated steps with clear and highly specific mechanisms.
First, following oral absorption of metronidazole capsules 500mg, free meronidal molecules freely penetrate the cell membranes of susceptible anaerobic bacteria and protozoa via passive diffusion, rapidly entering pathogenic microorganisms without carrier assistance and evenly distributing within the cytoplasm.
Aerobic bacteria and mammalian human cells lack specific activating enzyme systems to activate meronidal, so the drug exerts no damage to normal human cells or aerobic bacteria and boasts favorable medication safety.
Second, inside anaerobic microbes, the low redox potential environment activates microorganism-specific electron transport proteins such as ferredoxin and pyruvate:ferredoxin oxidoreductase. These proteins transfer intracellular electrons to the nitro group (-NO₂) of meronidal, triggering a specific reduction reaction that generates highly cytotoxic active metabolites including nitroso free radicals and hydroxylamine derivatives.
This reduction continuously consumes intracellular electrons and forms a drug concentration gradient, further driving additional extracellular meronidal molecules into bacterial cells to amplify anti-infective efficacy. Meanwhile, the reduction depletes key intracellular metabolic substances of microbes, blocks their normal energy synthesis pathways, deprives pathogens of energy and disrupts metabolism, preventing their proliferation and physiological metabolic activities.
Finally, the generated toxic active products directly bind to pathogen deoxyribonucleic acid (DNA), precisely targeting the double-stranded DNA structure to induce DNA strand breakage, base mispairing and helical depolymerization damage, thoroughly inhibiting microbial DNA replication, transcription and repair. Unlike the bacteriostatic effects of ordinary antibiotics, meronidal causes irreversible genomic damage to pathogenic microorganisms, ultimately resulting in bacterial lysis and protozoan apoptosis to deliver complete bactericidal and parasiticidal outcomes.
In addition, meronidal mildly inhibits microbial ribosomal function and blocks protein synthesis, obstructing pathogen survival and proliferation from multiple dimensions to further strengthen anti-infective efficacy. For drug-resistant strains, its unique action pathway rarely induces cross-resistance, leading to relatively low clinical resistance incidence.
Clinical Applications in Anti-Anaerobic Bacterial Therapy
Anaerobic bacterial infections are common occult clinical conditions that can invade multiple human tissues and organs, characterized by insidious onset, pyogenic tendency, abscess formation and ineffectiveness of conventional antibiotics.
Metronidazole capsules 500mg represents the first-line agent for treating all types of anaerobic infections and covers the vast majority of common clinical anaerobic pathogens, including Bacteroides fragilis, Clostridium perfringens, Peptostreptococcus and Clostridium bacilli.
For digestive system infections, it serves as the primary therapeutic drug for intra-abdominal infections, pelvic infections, perforated appendicitis and peritonitis. Most intra-abdominal infections are mixed anaerobic infections dominated by highly pathogenic Bacteroides fragilis prone to infectious dissemination.
The high 500mg dosage rapidly achieves effective plasma concentrations, penetrates ascites and abscess walls to eliminate anaerobes within lesions and curb inflammatory spread.Clinically, it is often combined with broad-spectrum anti-aerobic antibiotics to cover all pathogens of mixed infections and markedly elevate cure rates. Moreover, it effectively treats pseudomembranous colitis: by eradicating pathogenic intestinal anaerobes and correcting intestinal flora imbalance induced by excessive Clostridioides difficile proliferation, it rapidly alleviates intestinal mucosal injury, diarrhea and abdominal pain.
In oral and maxillofacial infections, the closed, moist oral cavity serves as the primary colonization niche for anaerobes, which dominate pathogens of pericoronitis, periapical periodontitis, periodontal abscess and maxillofacial space infections. After oral administration of 500mg meronidal capsules, the drug quickly permeates periodontal tissues, alveolar bone and periapical lesions to precisely eliminate oral anaerobic pathogens, relieve local swelling, pain and suppuration, and block infection spread to deep maxillofacial spaces. It acts as the foundational anti-infective agent in stomatology. Compared with topical preparations, oral 500mg capsules maintain stable and long-lasting plasma concentrations, thoroughly eradicate deep occult lesions and lower infection recurrence risks.
For respiratory infections, it treats aspiration pneumonia, lung abscess and bronchiectasis complicated with anaerobic infections triggered by anaerobes. Such infections mostly arise from patients aspirating oral anaerobes, with lesions frequently located in dependent lung lobes and prone to pyogenic lesions unresponsive to routine antibiotics. The product penetrates lung tissue and abscess capsules to kill intralesional anaerobes, promote pus absorption and inflammation resolution, and effectively improve clinical manifestations including cough, foul purulent sputum and fever.
For skin, soft tissue and bone infections, it targets anaerobic infections from traumatic and postoperative wounds, pressure sore infections, osteomyelitis and pyomyositis. It eradicates deep-tissue anaerobic pathogens, inhibits wound suppuration and necrosis, accelerates wound healing, and is especially suitable for treating heavily contaminated traumas with anaerobic infection risks.
Clinical Applications in Antiprotozoal Therapy
Meronidal is the sole nitroimidazole drug with broad-spectrum antiprotozoal activity in clinical practice.
The standard 500mg dosage efficiently kills various pathogenic protozoa such as Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia, acting as the first-line therapeutic agent for diverse protozoal infectious diseases with definite efficacy and low recurrence rates.For trichomoniasis, a prevalent sexually transmitted disease, trichomonads colonize the female vagina, male urethra and prostate, triggering vulvar pruritus, abnormal vaginal discharge, frequent micturition and urgent urination, accompanied by high cross-transmission and recurrent episodes.
Regular oral treatment with 500mg meronidal capsules enables drug enrichment in genitourinary tissues, thoroughly eradicates trichomonads colonized deep within mucosal folds and glands, and disrupts protozoan proliferation niches. Standard full-course medication achieves radical cure; simultaneous treatment of sexual partners is required to eliminate recurrent cross-infection, making it the gold-standard drug for trichomonal vaginitis and urethritis.
For amebiasis, infection by Entamoeba histolytica may induce amebic dysentery and amebic liver abscess, potentially life-threatening in severe cases.
For intestinal amebic dysentery, 500mg meronidal capsules directly target intestinal mucosal lesions, kill amebic trophozoites in the intestinal lumen and mucosal layers, relieve abdominal pain, mucoid bloody diarrhea and loose stools, and rapidly control acute intestinal infections.For extraintestinal amebiasis such as amebic liver and lung abscesses, the drug penetrates abscess tissues via systemic circulation to eliminate trophozoites deep within lesions and accelerate abscess regression. Compared with traditional anti-amebic agents, it exerts faster onset and stronger tissue penetration, delivering effective monotherapy without combination with multiple medicines.
Additionally, it efficiently treats giardiasis: Giardia lamblia colonizes the human small intestine and causes persistent diarrhea, abdominal distension, dyspepsia and weight loss, predominantly transmitted via contaminated food and drinking water. Metronidazole capsules 500mg precisely eliminates intestinal giardial trophozoites, blocks protozoan invasion and injury to intestinal mucosa, rapidly restores intestinal digestive function, and achieves cure rates exceeding 90%, rendering it the preferred clinical drug for intestinal giardiasis. It also demonstrates remarkable therapeutic effects against rare pathogenic protozoan infections including dracunculiasis and balantidiasis.
Postoperative Infection Prophylaxis and Special-Scenario Applications
Surgical procedures, especially abdominal, pelvic, gastrointestinal, oral and gynecological operations, leave surgical wounds highly vulnerable to invasion by endogenous anaerobic pathogens, which may trigger complications including postoperative infection, incision suppuration and intra-abdominal abscess. Such complications elevate surgical risks and prolong patients' recovery periods.
Meronidal capsules 500 mg serves as a routine agent for the prophylaxis of postoperative anaerobic infections in clinical surgery. Regular preoperative administration sustains effective plasma drug concentrations throughout surgery and the postoperative phase, pre-inhibits the proliferation of endogenous anaerobes, blocks pathogen translocation and infection dissemination induced by surgical manipulation, and significantly reduces the incidence of postoperative infectious complications.
For gastrointestinal surgeries, the intestinal tract harbors massive quantities of anaerobes. Surgical manipulation frequently causes intestinal flora translocation and wound contamination. Combined perioperative use of 500 mg meronidal precisely eliminates intestinal pathogenic anaerobes, effectively prevents complications such as anastomotic site infection, intra-abdominal abscess and surgical incision infection, and optimizes surgical prognosis.
In gynecological surgery, uterine and pelvic operations involve confined anatomical cavities. Postoperative local hemostasis and wound exudation readily foster anaerobic overgrowth, leading to pelvic inflammatory disease, intrauterine infection and incision infection.
Meronidal delivers broad coverage of common pelvic anaerobic pathogens, and the 500 mg dosage sustains long-lasting antibacterial activity to meet the anti-infective prophylaxis requirements after gynecological operations.
Furthermore, this drug is indicated for the treatment of bacterial vaginosis. It targets vaginal flora disturbance, malodorous vaginal discharge and vaginitis caused by excessive proliferation of anaerobes such as Gardnerella vaginalis. By suppressing anaerobic multiplication and restoring the normal balance of vaginal microflora, it achieves targeted symptomatic treatment with favorable safety profiles and consistent therapeutic efficacy.
Step 1: Nitration Reaction
2-methylimidazole is adopted as the base raw material, with concentrated sulfuric acid serving as catalyst and reaction medium. Fuming nitric acid is slowly added dropwise under low-temperature conditions for nitration modification.
The reaction temperature is precisely controlled at 0–5°C to avoid side reactions such as over-nitration and imidazole ring cleavage induced by high temperatures, enabling selective substitution of the nitro group at the C5 carbon atom of the imidazole ring to generate the intermediate 2-methyl-5-nitroimidazole. Post-reaction procedures include neutralization, filtration and recrystallization purification to remove impurities and residual acid liquor, yielding high-purity intermediate.
Step 2: Hydroxyethylation Reaction
Purified 2-methyl-5-nitroimidazole is dissolved in alkaline ethanol solution, followed by addition of ethylene oxide as the hydroxyethylation reagent under constant-temperature stirring. A hydroxyethyl functional group is introduced onto the N1 nitrogen atom of the imidazole ring to generate crude meronidal.
The crude product undergoes vacuum distillation, decolorization, recrystallization and drying refinement to obtain meronidal active pharmaceutical ingredient (API) with purity ≥99.8%, complying with pharmacopoeial pharmaceutical standards.
This industrially optimized synthetic process avoids high material loss and excessive impurities associated with traditional high-temperature synthesis routes, featuring high raw material utilization and stable product properties. The prepared API can be directly filled into 500mg capsules with stable pharmaceutical efficacy and extremely low impurity content, meeting clinical medication safety specifications.
FAQ
What two infections can be treated with metronidazole?
+
-
Metronidazole is a widely prescribed antibiotic used to treat a variety of bacterial and parasitic infections. Two common infections treated with metronidazole include:
Bacterial Vaginosis (BV): A common vaginal condition caused by an overgrowth of harmful bacteria. It is typically treated with oral tablets or an intravaginal gel.
Trichomoniasis: A common sexually transmitted infection (STI) caused by a parasite. It is usually cured with a single, high-dose oral treatment, and both sexual partners must be treated to prevent reinfection.
What is metronidazole used for in STDs?
+
-
Metronidazole is primarily used to treat trichomoniasis, a common parasitic sexually transmitted infection (STI). It is also used to treat bacterial vaginosis (BV) and forms of pelvic inflammatory disease (PID), which can occur alongside other STIs.
How long does it take for metronidazole to clear up a bacterial infection?
+
-
Metronidazole starts working within a few hours, but it typically takes 2 to 3 days to notice symptom relief and 5 to 14 days to completely clear the infection.
Hot Tags: metronidazole capsules 500mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale